VNTH / Nano Mobile Healthcare, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Nano Mobile Healthcare, Inc. UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED JUNE 30, 2023

Exhibit 12.1 Nano Mobile Healthcare, Inc. UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED JUNE 30, 2023 TABLE OF CONTENTS DESCRIPTION PAGE Financial Statements Statement of Assets and Liabilities 2 Statement of Operations 3 Statement of Changes in Partners' Capital 4 Statements of Cash Flows 5 Notes To Accompanied Financial Statements 6 – 13 Supplementary Information Schedules of

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 1-A Dated: December 29, 2023 REGULATION A OFFERING CIRCULAR UNDER THE SECURITIES ACT OF 1933 Nano Mobile Healthcare, Inc. (Exact name of issuer as specified in its charter) Delaware (S

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 1-A Dated: December 29, 2023 REGULATION A OFFERING CIRCULAR UNDER THE SECURITIES ACT OF 1933 Nano Mobile Healthcare, Inc. (Exact name of issuer as specified in its charter) Delaware (State of other jurisdiction of incorporation or organization) ONE BOSTON PLACE, SUITE 2600 BOSTON, MASSACHUSETTS, 62108 424-358-1046 (Address, includin

AMENDED AND RESTATED BYLAWS NANO MOBILE HEALTHCARE, INC. ARTICLE I. OFFICES

Exhibit 2.2 AMENDED AND RESTATED BYLAWS OF NANO MOBILE HEALTHCARE, INC. ARTICLE I. OFFICES Section 1.01 Principal Office. NANO MOBILE HEALTHCARE, INC. (the “Corporation”) will maintain its principal office within or without the State of Delaware as the Board of Directors (the “Board”) may determine from time to time. Section 1.02 Registered Office and Other Offices. The registered office of the Co

NANO MOBILE HEALTHCARE, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION

Exhibit 2.1 NANO MOBILE HEALTHCARE, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION NANO MOBILE HEALTHCARE, INC. (the “Corporation”), a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: A. The original Certificate of Incorporation of the Corporation was filed with the Secretary of State of the State of Delaware on April 21, 2010 and ame

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Exhibit 6.3 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the use in the Offering Circular constituting a part of this Offering Statement on Form 1-A, as it may be amended, of our Independent Auditor’s Report dated March 17, 2023, relating to the audit of the financial statements for the period ending December 31, 2022 and 2021 of Nano Mobile Healthcare, Inc., and the refe

For the Period Ended December 31, 2022 and 2021

Exhibit 12.1 NANO MOBILE HEALTHCARE, INC. FINANCIAL STATEMENTS For the Period Ended December 31, 2022 and 2021 TOGETHER WITH INDEPENDENT AUDITOR’S REPORT March 17, 2023 Haroon Imtiaz, CPA Mountain House, CA 95391 T: +1(415) 814-9445 E: [email protected] TABLE OF CONTENTS DESCRIPTION PAGE Independent Accountants' Audit Report 1 – 2 Financial Statements Statement of Assets and Liabilities 3

NANO MOBILE HEALTHCARE, INC. SUBSCRIPTION AGREEMENT NOTICE TO INVESTORS

Exhibit 4.1 NANO MOBILE HEALTHCARE, INC. SUBSCRIPTION AGREEMENT NOTICE TO INVESTORS THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK. THIS INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, INVESTORS MUST UNDERSTAND THAT SUCH INVESTMENT IS ILLIQUID AND IS EXPECTED TO CONTINUE TO BE I

Alpha Advocate Law Group PC 11432 South Street, #373 Cerritos, CA 90703,

Exhibit 12.1 Alpha Advocate Law Group PC 11432 South Street, #373 Cerritos, CA 90703, 310-866-6018 [email protected] December 28, 2023 Roy Watson Chief Executive Officer Nano Mobile Healthcare, Inc. One Boston Place, Suite 2600 Boston, Massachusetts 62108 Dear Ms. Gruel: I have acted, at your request, as special counsel to Nano Mobile Healthcare, Inc., a Delaware corporation (the “Company

1

Exhibit 3.1 1 2 3 4 5 6 7 8 9 10

EX-10.1

Exhibit 10.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2023 NANO MOBILE HE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2023 NANO MOBILE HEALTHCARE, INC. (Exact Name of Registrant as Specified in its Charter) Nevada (State or other jurisdiction of incorporation) 000-55155 (Commission File

EX-10.2

Exhibit 10.2

Audit Report

Exhibit 10.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 NANO MOBILE HEAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 NANO MOBILE HEALTHCARE, INC. (Exact Name of Registrant as Specified in its Charter) Nevada (State or other jurisdiction of incorporation) 000-55155 (Commission File N

Board Resolution for the resignation, and appointment of Officers

Exhibit 10.2

Securities Purchase Agreement

Exhibit 10.1

Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2022 NANO MOBILE HEALTHCARE, INC. (Exact Name of Registrant as Specified in its Charter) Nevada (State or other jurisdiction of incorporation) 000-55155 (Commission File

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2022 NANO MOBILE HEALTHCARE, INC. (Exact Name of Registrant as Specified in its Charter) Nevada (State or other jurisdiction of incorporation) 000-55155 (Commission File N

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2022 NANO MOBILE HEALTHCARE, INC. (Exact Name of Registrant as Specified in its Charter) Nevada (State or other jurisdiction of incorporation) 000-55155 (Commission File N

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2022 NANO MOBILE HEALTHCARE, INC. (Exact Name of Registrant as Specified in its Charter) Nevada (State or other jurisdiction of incorporation) 000-55155 (Commission File N

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2021 NANO MOBILE HEALTHCARE, INC. (Exact Name of Registrant as Specified in its Charter) Nevada (State or other jurisdiction of incorporation) 000-55155 (Commission File N

10.15.2021 Press Release

Exhibit 2.1 Nano Mobile Moves into Gaming/Crypto with New CEO David Noah Kittle TORRANCE, CA October 15, 2021 (GLOBAL NEWSWIRE) -Nano Mobile ?the Company? (OTC: VNTH TWTR: @NanoTechCrypto), a gaming, crypto and NFT engagement company, presents David Noah Kittle as Chief Executive Officer of Nano Mobile Tech. ?I?m honored and excited to come on board with Nano Mobile to help steer the company towar

Financial Statements and Exhibits, Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2021 NANO MOBILE HEALTHCARE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation) 000-55155 (Commission File

10.14.2021 Settlement Agreement

Exhibit 10.1 SETTLEMENT AGREEMENT THIS SETTLEMENT AGREEMENT (the ?Agreement?) is made and entered into as of October 6, 2021, by and among VIS VIRES GROUP, INC. (?VVG?), a corporation formed and existing pursuant to the laws of the State of New York and having a principal place of business located at 111 Great Neck Road, Suite 216, Great Neck, New York 11021 and NANO MOBILE HEALTHCARE, INC. f/k/a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13

15-12G 1 form15.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 000-55155 NANO MOBILE HEALTHCARE, INC. (Exact name of r

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2019 NANO MOBILE HEALTHCARE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation) 000-55155 (Commission File

Other Events

8-K 1 s6241908k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2019 NANO MOBILE HEALTHCARE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 000-55155 98-0659770 (State or other jurisdiction of inc

VNTH / Nano Mobile Healthcare, Inc. PRE 14C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement NANO MOBILE HEALTHCARE, INC. (Name o

Certificate of Amendment of the Certification of Incorporation of Nano Mobile Healthcare, Inc. to complete a reverse split of the series A Preferred stock of Nano Mobile Healthcare, Inc. dated May 24, 2018

Exhibit 3.2 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION TO COMPLETE A REVERSE SPLIT OF THE SERIES A PREFERRED STOCK OF NANO MOBILE HEALTHCARE, INC. It is hereby certified that: 1. The current name of the corporation is Nano Mobile Healthcare, Inc. (the “Corporation”). 2. The Corporation filed its Certificate of Incorporation with the Delaware Secretary of State on January 9, 2015

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

8-K 1 j6131818k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: June 15, 2018 (Date of earliest event reported): February 27, 2018 NANO MOBILE HEALTHCARE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incor

Certificate of Incorporation to lower the authorized shares of Series A Preferred to 2,347,337 and clarify the number of Authorized shares of the Convertible Preferred, dated June 6, 2018.

Exhibit 3.3 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION TO LOWER THE AUTHORIZED SHARES OF SERIES A PREFERRED AND CLARIFY THE COMPANY’S PREFERRED STOCK OF NANO MOBILE HEALTHCARE, INC. It is hereby certified that: 1. The current name of the corporation is Nano Mobile Healthcare, Inc. (the “Corporation”). 2. The Corporation filed its Certificate of Incorporation with the Delaware Sec

Certificate of Amendment of the Certification of Incorporation of Nano Mobile Healthcare, Inc. increasing the authorized shares of Common Stock from 900,000,000 shares to 100,000,000,000, approve the Corporation’s reverse split of its common stock in a ratio of between 1 for 10 to 1 for 100,000, such ratio to be determined by the Corporation’s board of directors and reduce the par value of the Corporation’s Common Stock and the Convertible Preferred Stock to $.00001 dated March 5, 2018.

Exhibit 3.1 Certificate of Amendment to the Certificate of Incorporation of Nano Mobile Healthcare, Inc. . It is hereby certified that: 1. The current name of the corporation is Nano Mobile Healthcare, Inc. (the “Corporation”). 2. The Corporation filed its Certificate of Incorporation with the Delaware Secretary of State on January 9, 2015 under the name Vantage mHealthcare, Inc. and filed an Amen

VNTH / Nano Mobile Healthcare, Inc. / Finnegan Cara Marie Activist Investment

SC 13D 1 j67180sc13d.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Nano Mobile Healthcare, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 63010B200 (CUSIP Number) Surinder Ahuwalia Ahluwalia Law Group 1212 Hancock Street, Suite LL 10 Quincy, MA 02169 Telephone 617-874-1390 (N

VNTH / Nano Mobile Healthcare, Inc. / Groman John E Activist Investment

SC 13D 1 r67180sc13d.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Nano Mobile Healthcare, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 63010B200 (CUSIP Number) Surinder Ahuwalia Ahluwalia Law Group 1212 Hancock Street, Suite LL 10 Quincy, MA 02169 Telephone 617-874-1390 (N

VNTH / Nano Mobile Healthcare, Inc. / Swan Allison Carol Activist Investment

SC 13D 1 g67180sc13d.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Nano Mobile Healthcare, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 63010B200 (CUSIP Number) Robert E. Braun, Esq. Jeffer Mangels Butler & Mitchell LLP 1900 Avenue of the Stars, 7th Floor Los Angeles, CA 90

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

8-K 1 f8-k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 16, 2018 Nano Mobile Healthcare, Inc. (Exact name of registrant as specified in charter) DELAWARE (State or other jurisdiction of incorporation) 000-5515

VNTH / Nano Mobile Healthcare, Inc. QUARTERLY REPORT (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2016 ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-55155 Nano Mobile Healthcare, Inc

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

8-K 1 mainbody.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 31, 2017 (May 23, 2017) NANO MOBILE HEALTHCARE, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-55155 93-0659770 (State or other jurisd

VNTH / Nano Mobile Healthcare, Inc. 10-K (Annual Report)

10-K 1 mainbody.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2016 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the transition period from to Commission file number: 000-55155 Nano Mobile Healthcare, Inc.

November 14, 2016 Letter Agreement

KINERET KALLMAN November 14, 2016 Nano Mobile Healthcare Inc. Three Columbus Circle 15th Floor New York, NY 10019 Attn: Joe Peters Kineret Kallman (the “Owner”) is the owner of certain notes (the “Notes”) of Nano Mobile Healthcare Inc. (the “Company”) and Owner may have certain claims against the Company relating to the Notes. For good and valuable consideration, the receipt of which is hereby ack

Global Settlement & Mutual Release

GLOBAL SETTLEMENT AGREEMENT& MUTUAL RELEASE OF ALL CLAIMS BY ALL PARTIES THIS GLOBAL SETTLEMENT AGREEMENT & MUTUAL RELEASE OF ALL CLAIMS BY ALL PARTIES (“Agreement”) is dated, entered into and made fully effective (irrespective of the date actually signed by the parties) as of the 10th day of March, 2017, by and among JDF Capital, Inc.

Certificate of Designation

CERTIFICATE OF DESIGNATION OF RIGHTS, PREFERENCES, PRIVILEGES AND RESTRICTIONS OF SERIES B CONVERTIBLE PREFERRED STOCK OF NANO MOBILE HEALTHCARE, INC.

Settlement Agreement

SETTLEMENT AGREEMENT THIS SETTLEMENT AGREEMENT (the “Agreement”) is made and entered into on this 24th day of April, 2017, by and among Navesink River Capital, LLC (hereinafter Navesink), and Adam 2, L.

Nano Mobile Healthcare /A (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 2 [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2012 [ ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 333-168930 Nano

Nano Mobile Healthcare /A (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 2 [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2012 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the transition period from to Commission file number: 333-168930 Nano Mobile Healthcare, Inc.

Nano Mobile Healthcare /A (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 2 [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2011 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the transition period from to Commission file number: 333-168930 Nano Mobile Healthcare, Inc.

Nano Mobile Healthcare 0-K

NT 10-K 1 nt10-k.htm U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 000-55155 Notification of Late Filing (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form N-SAR For Period Ended: June 30, 2016 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report

Nano Mobile Healthcare (Quarterly Report)

10-Q 1 form10-q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2016 [ ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-55155 Nano Mo

Nano Mobile Healthcare 0-Q

NT 10-Q 1 mainbody.htm U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 000-55155 Notification of Late Filing (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR For Period Ended: March 31, 2016 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Rep

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

8-K 1 mainbody.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2016 NANO MOBILE HEALTHCARE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 000-55155 93-0659770 (State or other jurisdiction of inc

Reverse Stock Split Certificate of Amendment of the Certificate of Incorporation of Nano Mobile Healthcare, Inc

CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF NANO MOBILE HEALTHCARE, INC.

Increase in Authorized Shares Certificate of Amendment of the Certificate of Incorporation of Nano Mobile Healthcare, Inc.

CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF NANO MOBILE HEALTHCARE, INC.

Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

CERTIFICATIONS I, Joseph C. Peters, certify that; 1. I have reviewed this quarterly report on Form 10-Q for the quarter ended December 31, 2015 of Nano Mobile Healthcare, Inc. (the “registrant”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under w

Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

CERTIFICATIONS I, Joseph C. Peters, certify that; 1. I have reviewed this quarterly report on Form 10-Q for the quarter ended December 31, 2015 of Nano Mobile Healthcare, Inc. (the ?registrant?); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under w

Nano Mobile Healthcare /A (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1 [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2015 [ ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-55155 Nano M

VNTH / Nano Mobile Healthcare, Inc. 10-Q - Quarterly Report -

10-Q 1 mainbody.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2015 [ ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-55155 Nano

Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

CERTIFICATIONS I, Joseph C. Peters, certify that; 1. I have reviewed this quarterly report on Form 10-Q for the quarter ended December 31, 2015 of Nano Mobile Healthcare, Inc. (the “registrant”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under w

Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

CERTIFICATIONS I, Joseph C. Peters, certify that; 1. I have reviewed this quarterly report on Form 10-Q for the quarter ended December 31, 2015 of Nano Mobile Healthcare, Inc. (the “registrant”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under w

Nano Mobile Healthcare 0-Q

NT 10-Q 1 nt10-q.htm U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 000-55155 Notification of Late Filing (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR For Period Ended: December 31, 2015 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Re

Nano Mobile Healthcare 14C

PRE 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [ ] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [X] Definitive Information Statement Nano Mobile Healthcare

Nano Mobile Healthcare 14C

PRER14C 1 prer14c.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. 1) Check the appropriate box: [X] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [ ] Definitive Information

Nano Mobile Healthcare 14C

PRE 14C 1 pre14c.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [X] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [ ] Definitive Information Statement Nano Mobi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No 1 [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2015 [ ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-55155 Nano M

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

10-Q 1 form10-q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2015 [ ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-55155 Nan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

10-K 1 form10-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2015 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the transition period from to Commission file number: 000-55155 Nano Mobile Healthcare, Inc.

Nano Mobile Healthcare 0-K

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 000-55155 Notification of Late Filing (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form N-SAR For Period Ended: June 30, 2015 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Tra

Certificate of amendment TO THE CERTIFICATE OF INCORPORATION VANTAGE mHEALTHCARE, iNC. (Pursuant to Section 242 of the Delaware General Corporation Law)

Certificate of amendment TO THE CERTIFICATE OF INCORPORATION OF VANTAGE mHEALTHCARE, iNC.

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2015 Nano Mobile Healthcare, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55155 93-0659770 (State or other jurisdiction of i

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2015 VANTAGE mHEALTHCARE, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55155 93-0659770 (State or other jurisdiction of incorp

CERTIFICATE OF DESIGNATION RIGHTS, PREFERENCES, PRIVILEGES AND RESTRICTIONS SERIES A CONVERTIBLE PREFERRED STOCK VANTAGE mHEALTHCARE, INC.

CERTIFICATE OF DESIGNATION OF RIGHTS, PREFERENCES, PRIVILEGES AND RESTRICTIONS OF SERIES A CONVERTIBLE PREFERRED STOCK OF VANTAGE mHEALTHCARE, INC.

EXCHANGE AGREEMENT

EXCHANGE AGREEMENT This Exchange Agreement is dated and effective as of August 25, 2015 (this ?Agreement?) and is entered into by and between Vantage mHealthcare, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1) [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2015 [ ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-55155 Vantage

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2015 [ ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-55155 Vantage mHealthcare, Inc. (

VNTH / Nano Mobile Healthcare, Inc. / Groman John E Activist Investment

SC 13D/A 1 sc13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1) Under the Securities Exchange Act of 1934 VANTAGE MHEALTHCARE, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 92210G107 (CUSIP Number) John E. Groman c/o Surinder Ahluwalia Ahluwalia Law Group 1212 Hancock Street, Suite LL10 Quincy, MA 02

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

10-Q 1 form10-q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2014 [ ] Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-55

CERTIFICATE OF INCORPORATION VANTAGE mHEALTHCARE, INC.

EXHIBIT 3.1 CERTIFICATE OF INCORPORATION OF VANTAGE mHEALTHCARE, INC. The undersigned, a natural person, for the purpose of organizing a corporation for conducting the business and promoting the purposes hereinafter stated, under the provisions and subject to the requirements of the laws of the State of Delaware (particularly Chapter 1, Title 8 of the Delaware Code and the acts amendatory thereof

Vantage Health Announces Corporate Name Change to Vantage mHealthcare, Inc. Company Amends State of Incorporation to Delaware

EXHIBIT 99.1 Vantage Health Announces Corporate Name Change to Vantage mHealthcare, Inc. Company Amends State of Incorporation to Delaware New York, NY – January 9, 2015 – Vantage mHealthcare, Inc. (OTCQB: VNTH) (“Vantage Health” or the “Company”) today announced that the corporate name has officially changed to Vantage mHealthcare, Inc. to better align the strategic direction of the Company withi

AMENDED AND RESTATED BYLAWS VANTAGE mHEALTHCARE, INC. (the “Corporation”) As of January 6, 2015 ARTICLE I: MEETINGS OF STOCKHOLDERS

EXHIBIT 3.2 AMENDED AND RESTATED BYLAWS OF VANTAGE mHEALTHCARE, INC. (the “Corporation”) As of January 6, 2015 ARTICLE I: MEETINGS OF STOCKHOLDERS SECTION 1 - ANNUAL MEETINGS An annual meeting of the stockholders, for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, on

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

8-K 1 form8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2015 VANTAGE mHEALTHCARE, INC. (Exact name of registrant as specified in its charter) Delaware 333-168930 93-0659770 (State or other jurisdiction of incorp

VNTH / Nano Mobile Healthcare, Inc. DEF 14C - - DEFINITIVE INFORMATION STATEMENT

Schedule 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Check the appropriate box: [ ] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [X] Definitive Information Statement

VNTH / Nano Mobile Healthcare, Inc. PRER14C - - PRELIMINARY REVISED INFORMATION STATEMENT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. 1 ) Check the appropriate box: [X] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [ ] Definitive Information Statement VANTAGE HEA

VNTH / Nano Mobile Healthcare, Inc. CORRESP - -

Avisheh Avini | 212 692 6200 | [email protected] Chrysler Center 666 Third Avenue New York, NY 10017 212-935-3000 212-983-3115 fax www.mintz.com December 12, 2014 Via EDGAR and Federal Express Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Jeffrey P. Riedler Re: Vantage Health Preliminary Proxy Statement on Schedule 14C Filed No

VNTH / Nano Mobile Healthcare, Inc. PRE 14C - - PRE 14C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Check the appropriate box: [X] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [ ] Definitive Information Statement VANTAGE HEALT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2014 [ ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-55155 Vantage Health (Exact n

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 1 [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2014 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the transition period from to Commission file number: 000-55155 Vantage Health (Exact name of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

10-K 1 mainbody.htm MAINBODY UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2014 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the transition period from to Commission file number: 000-55155 Vantage Health (Exa

Vantage Health Announces Appointment of Edward Rollins, Former Advisor to Four U.S. Presidents, to Its Board of Directors

EXHIBIT 99.1 Vantage Health Announces Appointment of Edward Rollins, Former Advisor to Four U.S. Presidents, to Its Board of Directors Redwood City, CA – September 29, 2014 – Vantage Health Inc., (OTCQB: VNTH) (“Vantage Health” or (the “Company”) today announced the appointment of Edward Rollins to its Board of Directors. Mr. Rollins currently serves as a senior advisor for Teneo, a global advisor

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events, Financial Statements and Exhibits

8-K 1 form8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2014 VANTAGE HEALTH (Exact name of registrant as specified in its charter) Nevada 333-168930 93-0659770 (State or other jurisdiction of incorporation) (

VNTH / Nano Mobile Healthcare, Inc. NT 10-K - - MAINBODY

NT 10-K 1 mainbody.htm MAINBODY U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 333-168930 Notification of Late Filing (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form N-SAR For Period Ended: June 30, 2014 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Trans

Tony van Bijleveld, General Manager for Patheon/DPX, and former General Manager Europe for Alliance Boots Walgreens, Appointed to the Vantage Health Board of Directors

EX-99.1 2 ex99-1.htm Tony van Bijleveld, General Manager for Patheon/DPX, and former General Manager Europe for Alliance Boots Walgreens, Appointed to the Vantage Health Board of Directors Redwood City, CA – September 22, 2014 – Vantage Health Inc., (OTCQB: VNTH) (“Vantage Health”) or (the “Company”) today announced the appointment of Tony van Bijleveld as an independent member of the Board of Dir

Vantage Health Announces Appointment of Joseph C. Peters, former White House Drug Policy Office’s Acting Deputy Director for State and Local Affairs under Presidents Clinton and Bush, to Its Board of Directors

EX-99.3 4 ex99-3.htm Vantage Health Announces Appointment of Joseph C. Peters, former White House Drug Policy Office’s Acting Deputy Director for State and Local Affairs under Presidents Clinton and Bush, to Its Board of Directors Redwood City, CA – September 24, 2014 – Vantage Health Inc., (OTCQB: VNTH) (“Vantage Health”) or (the “Company”) today announced the appointment of Joseph C. Peters to i

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

8-K 1 form8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2014 VANTAGE HEALTH (Exact name of registrant as specified in its charter) Nevada 333-168930 93-0659770 (State or other jurisdiction of incorporation) (

Vantage Health Names Dr. Steven R. Steinhubl, Director of Digital Medicine at Scripps Translational Science Institute, New Chairman of the Board

EXHIBIT 99.2 Vantage Health Names Dr. Steven R. Steinhubl, Director of Digital Medicine at Scripps Translational Science Institute, New Chairman of the Board Redwood City, CA – September 23, 2014 – Vantage Health Inc., (OTCQB: VNTH) (“Vantage Health”) or (the “Company”) today announced the appointment of Steven R. Steinhubl, M.D. as chairman of the board. Dr. Steinhubl replaces interim chairman, D

Dr Kevin Buckman Named Chairman and CEO of Vantage Health -Preliminary human clinical trials are anticipated to begin next month-

Dr Kevin Buckman Named Chairman and CEO of Vantage Health -Preliminary human clinical trials are anticipated to begin next month- Redwood City, CA – July 29, 2014 – Vantage Health (the “Company”) (OTCQB: VNTH) today announced the appointment of Kevin Buckman MD FAAIM, DAAUCM, MACOEM, MRO as Chairman and CEO of the Company.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

8-K 1 form8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(D) of the Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): July 29, 2014 Vantage Health (Exact name of registrant as specified in its charter.) Nevada 000-55155 93-0659770 (State or other jurisdiction (Commissi

VNTH / Nano Mobile Healthcare, Inc. POS AM - -

POS AM 1 formposam.htm As filed with the Securities and Exchange Commission on July 24, 2014 Registration No. 333-168930 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VANTAGE HEALTH (Exact name of registrant as specified in its charter) Nevada 93-0659770 (State or other juri

VNTH / Nano Mobile Healthcare, Inc. / Groman John E - SCHEDULE 13D Activist Investment

SC 13D 1 formsc13d.htm SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* VANTAGE HEALTH (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 92210G107 (CUSIP Number) John E. Groman c/o Surinder Ahluwalia Ahluwalia Law Group 1212 Hancock Street, Suite LL10 Quincy, MA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2014 [ ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-55155 Vantage Health (Exact name

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2014 VANTAGE HEALTH (Exact name of registrant as specified in its charter) Nevada 000-55155 93-0659770 (State or other jurisdiction of incorporation) (Commission File Number

Letter from Silberstein Unger PLLC to the Securities and Exchange Commission

Silberstein Ungar, PLLC CPAs and Business Advisors Phone (248) 203-0080 Fax (248) 281-0940 30600 Telegraph Road, Suite 2175 Bingham Farms, MI 48025-4586 www.

- MAINBODY

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Vantage Health (Exact name of registrant as specified in its charter) Nevada 93-0659770 (State of incorporation or organization) (I.R.S. Employer Identification No.) 401 Warrent St. Suite 200 Redwood City, CA 940

Sublicense Agreement by and between Nanobeak, Inc. and Vantage Health dated February 20, 2014

SUBLICENSE AGREEMENT This Sublicense Agreement (“Agreement”), effective as of the date of last signature below (the “Effective Date”), is by and between Nanobeak, Inc.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits - MAINBODY

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2014 VANTAGE HEALTH (Exact name of registrant as specified in its charter) Nevada 333-168930 93-0659770 (State or other jurisdiction of incorporation) (Commission File Nu

License Agreement*

LICENSE AGREEMENT NATIONAL AERONAUTICS AND SPACE ADMINISTRATION AND NANOBEAK INC. (PARTIALLY) EXCLUSIVE LICENSE AGREEMENT No. DE- LICENSE COMMENCEMENT DATE: 12/31/13 Portions of this exhibit, indicated by the mark “[***],” have been redacted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Securities and Exchange Commission. TAB

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2013 [ ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 333-168930 Vantage Health (Exact n

- MAINBODY

NT 10-Q 1 mainbody.htm MAINBODY U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 0001497130 Notification of Late Filing (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [x] Form 10-Q [ ] Form N-SAR For Period Ended: December 31, 2013 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] T

BIOA / BioAmber Inc. / Accent Healthcare Advisors LLC Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* VANTAGE HEALTH (Name of Issuer) Common Stock, $.01 par value (Title of Class of Securities) 92210G107 (CUSIP Number) Allison C. Swan c/o Robert E. Braun Jeffer Mangels Butler & Mitchell LLP 1900 Avenue of the Stars, 7th Floor Los Angeles, CA 90067 Telepho

Vantage Health Receives License After NASA and Nanobeak Enter into an Exclusive Five-Year Commercial License Agreement

EXHIBIT 99.1 Vantage Health Receives License After NASA and Nanobeak Enter into an Exclusive Five-Year Commercial License Agreement Redwood City, CA – January 7, 2014 – Vantage Health Inc, (OTCB: VNTH) and its parent company Nanobeak Inc. today announced that NASA and Nanobeak have entered into an exclusive 5-year license agreement to commercialize mobile healthcare products derived from NASA pate

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events - CURRENT REPORT

FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 1, 2014 VANTAGE HEALTH (Exact name of registrant as specified in its charter) Nevada 333-168930 93-0659770 (State or other jurisdiction of incorporation) (Commission

Unregistered Sales of Equity Securities, Financial Statements and Exhibits

8-K 1 form8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2013 VANTAGE HEALTH (Exact name of registrant as specified in its charter) Nevada 333-168930 93-0659770 (State or other jurisdiction of in

STOCK PURCHASE WARRANT

THIS WARRANT AND THE SHARES ISSUABLE UPON THE EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

Current Report

8-K 1 form8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2013 VANTAGE HEALTH (Exact name of registrant as specified in its charter) Nevada 333-168930 93-0659770 (State or other jurisdiction of in

Dr. William S. Rees, Jr., former Deputy Under Secretary of Defense is appointed to the Vantage Health Board of Directors

EX-99.1 5 ex99-1.htm EXHIBIT 99.1 Dr. William S. Rees, Jr., former Deputy Under Secretary of Defense is appointed to the Vantage Health Board of Directors Redwood City, CA – December 18, 2013 – Vantage Health Inc, (OTCQB: VNTH) today announced the appointment of Dr. William S. Rees, Jr., as the first independent member of the Board of Directors of Vantage Health, Inc. Dr. William S. Rees, Jr. serv

Vantage Health, Inc. DIRECTOR RETAINER AGREEMENT

Vantage Health, Inc. DIRECTOR RETAINER AGREEMENT THIS RETAINER AGREEMENT (this “Agreement”) is entered into by and between Vantage Health, Inc., a Nevada corporation (the “Company”), and William S. Rees, Jr. (“Director”) as of 16 December 2013. WHEREAS, Director has been elected as a director of the Company for a term ending on 31 December 2016; and WHEREAS, the Company wishes to compensate Direct

Right to Purchase 2,000,000 Shares of Common Stock, par value $.01 per share STOCK PURCHASE WARRANT

THIS WARRANT AND THE SHARES ISSUABLE UPON THE EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

INDEMNIFICATION AGREEMENT

EX-10.1 3 ex10-1.htm EXHIBIT 10.1 INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is dated as of 16 December 2013, and is between Vantage Health, Inc., a Nevada corporation (the “Company”), and William S. Rees, Jr. (“Indemnitee”). RECITALS A. Indemnitee’s service to the Company substantially benefits the Company. B. Individuals are reluctant to serve as directors or off

JOINT FILING AGREEMENT

Exhibit 1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of November 18, 2013, is by and between Nanobeak, Inc.

VNTH / Nano Mobile Healthcare, Inc. / NANOBEAK, INC. - SCHEDULE 13D Activist Investment

SC 13D 1 sc13d.htm SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 VANTAGE HEALTH (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 92210G107 (CUSIP Number) Vantage Health 2395 Broadway Street Redwood City, CA 94063 Telephone: (650) 503-3570 (Name, Address and Telephone

STOCK PURCHASE AGREEMENT By and Among BAYVIEW TERRACE LIMITED, as Seller, NANOBEAK, INC., as Buyer. November 7, 2013 TABLE OF CONTENTS

Exhibit 2 STOCK PURCHASE AGREEMENT By and Among BAYVIEW TERRACE LIMITED, as Seller, and NANOBEAK, INC.

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

8-K 1 form8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): November 7, 2013 VANTAGE HEALTH (Exact name of registrant as specified in its charter) Nevada 333-168930 93-0659770 (State or other jurisdiction of inc

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Unregistered Sales of Equity Securities

8-K 1 form8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 31, 2013 Vantage Health (Exact name of registrant as specified in its charter) NV 333-168930 93-0659770 (State or other jurisdiction of incorpo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2013 [ ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 333-168930 Vantage Health (Exact

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

8-K 1 mainbody.htm MAINBODY SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 15, 2013 Vantage Health (Exact name of registrant as specified in its charter) NV 333-168930 93-0659770 (State or other jurisdiction of incorporation) (Commission

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

8-K 1 mainbody.htm MAINBODY SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 9, 2013 Vantage Health (Exact name of registrant as specified in its charter) Nevada 333-168930 93-0659770 (State or other jurisdiction of incorporation) (Commis

Agreement of Conveyance, Transfer and Assignment of Subsidiary and Assumption of Obligations, dated October 9, 2013

AGREEMENT OF CONVEYANCE, TRANSFER AND ASSIGNMENT OF SUBSIDIARY AND ASSUMPTION OF OBLIGATIONS This Agreement of Conveyance, Transfer and Assignment of Subsidiary and Assumption of Obligations (“Transfer and Assumption Agreement”) is made as of September , 2013, by Vantage Health, a Nevada corporation (“Assignor”), Lisa Ramakrishnan (“Assignee”), and Moxisign (PTY) Ltd.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: June 30, 2013 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: June 30, 2013 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the transition period from to Commission file number: 333-168930 Vantage Health (Exact name of registrant as sp

- MAINBODY

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 333-168930 Notification of Late Filing (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form N-SAR For Period Ended: June 30, 2013 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Tr

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

8-K 1 mainbody.htm MAINBODY SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 14, 2013 Vantage Health (Exact name of registrant as specified in its charter) Nevada 333-168930 93-0659770 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2013 [ ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 333-168930 Vantage Health (Exact nam

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2012 [ ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 333-168930 Vantage Health (Exact n

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2012 [ ] Transition Report pu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2012 [ ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 333-168930 Vantage Health (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2012 [ ] Transition Report purs

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2012 [ ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 333-168930 Vantage Health (Exact

- MAINBODY

NT 10-K 1 mainbody.htm MAINBODY U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 333-168930 Notification of Late Filing (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form N-SAR For Period Ended: June 30, 2012 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Trans

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 28, 2012 Vantage Health (Exact name of registrant as specified in its charter) Nevada 333-168930 93-0659770 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Em

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Termination of a Material Definitive Agreement, Financial Statements and Exhibits - MAINBODY

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 14, 2012 Vantage Health (Exact name of registrant as specified in its charter) Nevada 333-168930 93-0659770 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. E

Addendum to Termination Agreement, dated May 15, 2012

Addendum to Termination Agreement IT IS THEREFORE AGREED AS FOLLOWS: 1. VH will pay to the nominee of P (being J Harris) the sum of US$ 32 000.00 as follows: 1. $ 5 000 on signature; 2. $ 3 000 each month on the first day thereof, the first payment due on or before 1 June 2012, until the whole amount is paid in full. 2. Such payment once made will be in full and final settlement of all civil claim

Letter from John Harris dated May 14 2012, withdrawal of allegations

John Harris Peninsula Holdings Ltd. 14 May 2012 To: The Board of Directors Vantage Health (INC. USA) Dear Sir RE: WITHDRAWAL OF LETTER OF RESIGNATION AND ALLEGATIONS I refer to my Notice of Resignation dated 4 May 2012. I unconditionally withdraw the above Letter of Resignation and withdraw each and every allegation made therein concerning Vantage Health and/or any Directors thereof, Including Lis

Letter from John Harris, dated May 14, 2012

John Harris May 14, 2012 To whom it may concern, RE: RESIGNATION AS CEO & DIRECTOR It is with regret that I tender my resignation from Vantage Health Ltd as CEO and Director, effective immediately, I also tender my resignation from all offices held by myself in subsidiaries of Vantage Health Ltd.

- MAINBODY

NT 10-Q 1 mainbody.htm MAINBODY U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 333-168930 Notification of Late Filing (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR For Period Ended: March 31, 2012 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Tran

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Termination of a Material Definitive Agreement, Financial Statements and Exhibits

8-K 1 mainbody.htm MAINBODY SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 14, 2012 Vantage Health (Exact name of registrant as specified in its charter) Nevada 333-168930 93-0659770 (State or other jurisdiction of incorporation) (Commiss

Settlement Agreement, dated April 14, 2012

Termination Agreement AGREEMENT Between JOHN HARRIS (JH) And PENINSULA HOLDINGS LTD.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

8-K 1 mainbody.htm MAINBODY SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 7, 2012 Vantage Health (Exact name of registrant as specified in its charter) Nevada 333-168930 93-0659770 (State or other jurisdiction of incorporation) (Commi

Employment Services Agreement, dated February 11, 2012

EX-10.1 2 ex101.htm EXHIBIT 10.1 EMPLOYMENT SERVICES AGREEMENT THIS AGREEMENT (“Agreement” or “Contract”) is between Peninsula Holdings Ltd, having its principal place of business in Victoria, Mahe, Seychelles ("Peninsula"); and Vantage Health, a publicly quoted Nevada Corporation having its principal place of business in Los Angeles, California, and Cape Town, South Africa ("Vantage"). WHEREAS, V

- MAINBODY

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 333-168930 Notification of Late Filing (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR For Period Ended: December 31, 2011 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [

Vantage Health Announces Appointment of New Chief Executive Officer

EX-99.1 3 ex991.htm EXHIBIT 99.1 Vantage Health Announces Appointment of New Chief Executive Officer CAPE TOWN, South Africa, Feb. 7, 2012 /PRNewswire via COMTEX/ - Vantage Health (OTC:BB - ticker symbol VNTH), ("Vantage", "Company"), announced today that it has appointed Mr. John A. Harris as a Director and Officer of the Company. Mr. Harris will assume the role of Chief Executive Officer. The cu

Commission File No. 333-168930 VANTAGE HEALTH (Name of registrant in its charter) Nevada (State or other jurisdiction of incorporation or organization) 98-0659770 (IRS Employer Identification Number) 11400 West Olympic Boulevard, Suite 640 Los Angele

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Mark One [ X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2011 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 333-168930 VANTAGE HEALTH (N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K /A [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2011 [ ] TRANSITION REPORT UNDER SECTION 13 OR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K /A [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2011 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the transition period from to Commission file number: 333-168930 Vantage Health (Exact name of registrant as

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25

NT 10-Q 1 mainbody.htm MAINBODY U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 333-168930 Notification of Late Filing (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR For Period Ended: September 30, 2011 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ]

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 333-168930

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 333-168930 X Form 10-K Form 20-F Form 11-K Form 10-Q Form 10-D Form N-SAR Form N-CSR For period ended: June 30, 2011 Transition Report on Form 10-K Transition Report on Form 20-F Transition Report on Form 11-K Transition Report on Form 10-Q Transition Report on Form N-SAR For the

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

10-Q 1 vantage10q033111.htm MARCH 31, 2011 10Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Mark One X . QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2011 . TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissi

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 333-168930

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 333-168930 Form 10-K Form 20-F Form 11-K X Form 10-Q Form 10-D Form N-SAR Form N-CSR For period ended: March 31, 2011 Transition Report on Form 10-K Transition Report on Form 20-F Transition Report on Form 11-K Transition Report on Form 10-Q Transition Report on Form N-SAR For th

Change in Shell Company Status

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 17, 20 11 Vantage Health (Exact name of registrant as specified in its charter) Nevada 333-168930 98-0659770 (State or other jurisdiction of (Commission File Number) (I.R.S. E

Change in Shell Company Status

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 17, 20 11 Vantage Health (Exact name of registrant as specified in its charter) Nevada 333-168930 98-0659770 (State or other jurisdiction of (Commission File Number) (I.R.S. Emp

CORRESP

VANTAGE HEALTH. From: Lisa Ramakrishnan Chief Executive Officer Suite 640-11400 West Olympic Boulevard Los Angeles, California, 90064-1567 AMMENDMENT #3 Re: Form S-1/A filed January 18, 2010 File No, 333-168930 To Whom It May Concern: On behalf of Vantage Health. a Nevada corporation (the "Company"), we submit the following responses which correspond to the numerical comments contained in the Secu

EX-10.8

Exhibit 10.8

S-1/A

S-1/A 1 g4787.htm As filed with the Securities and Exchange Commission on January 28, 2011 Registration No. 333-168930 ================================================================================ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMMENDMENT #4 TO FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VANTAGE HEALTH (Exact name of registrant as